Literature DB >> 17890779

Enhanced atherogenesis and altered high density lipoprotein in patients with Crohn's disease.

Sander I van Leuven1, Rachel Hezemans, Johannes H Levels, Susan Snoek, Pieter C Stokkers, G Kees Hovingh, John J P Kastelein, Erik S Stroes, Eric de Groot, Daan W Hommes.   

Abstract

A chronic inflammatory state is a risk factor for accelerated atherogenesis. The aim of our study was to explore whether Crohn's disease (CD), characterized by recurrent inflammatory episodes, is also associated with accelerated atherogenesis. In 60 CD patients and 122 matched controls, carotid intima media thickness (IMT), a validated marker for the burden and progression of atherosclerosis, was assessed ultrasonographically. Additional subgroup analyses, including plasma levels of acute phase reactants and HDL protein profiling, were performed in 11 consecutive patients with CD in remission, 10 patients with active CD, and 15 healthy controls. Carotid IMT in patients with CD was increased compared with healthy volunteers: 0.71 (0.17) versus 0.59 (0.14) mm (P < 0.0001), respectively. In the subgroup analysis, HDL levels in controls and patients in remission were identical [(1.45 (0.48) and 1.40 (0.46) mmol/l; P = 0.797], whereas HDL during exacerbation was profoundly reduced: 1.02 (0.33) (P = 0.022). HDL from patients with active CD and CD patients in remission was characterized by a reduced ability to attenuate oxidation compared with controls (P = 0.008 and P = 0.024 respectively). Patients with CD have increased IMT compared with matched controls, indicative of accelerated atherogenesis. The changes during CD exacerbation in terms of HDL concentration and composition imply a role for impaired HDL protection in these patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17890779     DOI: 10.1194/jlr.M700176-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  29 in total

1.  Evaluation of early atherosclerosis in patients with inflammatory bowel disease.

Authors:  Hasan Kayahan; Ismail Sari; Nesat Cullu; Fahize Yuksel; Serdal Demir; Mesut Akarsu; Yigit Goktay; Belkis Unsal; Hale Akpinar
Journal:  Dig Dis Sci       Date:  2012-04-01       Impact factor: 3.199

2.  Functional implications of disease-specific variants in loci jointly associated with coeliac disease and rheumatoid arthritis.

Authors:  Javier Gutierrez-Achury; Maria Magdalena Zorro; Isis Ricaño-Ponce; Daria V Zhernakova; Dorothée Diogo; Soumya Raychaudhuri; Lude Franke; Gosia Trynka; Cisca Wijmenga; Alexandra Zhernakova
Journal:  Hum Mol Genet       Date:  2015-11-05       Impact factor: 6.150

Review 3.  Cardiovascular complications in inflammatory bowel disease.

Authors:  Rudolf Schicho; Gunther Marsche; Martin Storr
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

4.  Use of atorvastatin as an anti-inflammatory treatment in Crohn's disease.

Authors:  O Grip; S Janciauskiene; A Bredberg
Journal:  Br J Pharmacol       Date:  2008-09-22       Impact factor: 8.739

5.  Transintestinal transport of the anti-inflammatory drug 4F and the modulation of transintestinal cholesterol efflux.

Authors:  David Meriwether; Dawoud Sulaiman; Alan Wagner; Victor Grijalva; Izumi Kaji; Kevin J Williams; Liqing Yu; Spencer Fogelman; Carmen Volpe; Steven J Bensinger; G M Anantharamaiah; Ishaiahu Shechter; Alan M Fogelman; Srinivasa T Reddy
Journal:  J Lipid Res       Date:  2016-05-19       Impact factor: 5.922

Review 6.  Risk of cardiovascular disease in inflammatory bowel disease.

Authors:  Nynne Nyboe Andersen; Tine Jess
Journal:  World J Gastrointest Pathophysiol       Date:  2014-08-15

Review 7.  The role of dysfunctional HDL in atherosclerosis.

Authors:  Mohamad Navab; Srinivasa T Reddy; Brian J Van Lenten; G M Anantharamaiah; Alan M Fogelman
Journal:  J Lipid Res       Date:  2008-10-27       Impact factor: 5.922

Review 8.  High-density lipoprotein and 4F peptide reduce systemic inflammation by modulating intestinal oxidized lipid metabolism: novel hypotheses and review of literature.

Authors:  Mohamad Navab; Srinivasa T Reddy; Brian J Van Lenten; Georgette M Buga; Greg Hough; Alan C Wagner; Alan M Fogelman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-11       Impact factor: 8.311

9.  Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus.

Authors:  Maureen McMahon; Jennifer Grossman; Brian Skaggs; John Fitzgerald; Lori Sahakian; Nagesh Ragavendra; Christina Charles-Schoeman; Karol Watson; Weng Kee Wong; Elizabeth Volkmann; Weiling Chen; Alan Gorn; George Karpouzas; Michael Weisman; Daniel J Wallace; Bevra H Hahn
Journal:  Arthritis Rheum       Date:  2009-08

Review 10.  HDL as a biomarker, potential therapeutic target, and therapy.

Authors:  Mohamad Navab; G M Anantharamaiah; Srinivasa T Reddy; Brian J Van Lenten; Alan M Fogelman
Journal:  Diabetes       Date:  2009-12       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.